Avoro Capital Advisors’s Terns Pharmaceuticals TERN Stock Holding History
Bought
Maintained
Sold
Other funds holding TERN
Avoro Capital Advisors's TERN Position: Q2 2026 in Review
Avoro Capital Advisors sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 5,695,000 shares — an estimated $300M sold.
Avoro Capital Advisors first reported a position in TERN in Q4 2025 and held it in 2 quarters. The position peaked at $300M in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.
- Avoro Capital Advisors reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Avoro Capital Advisors sold 5,695,000 Terns Pharmaceuticals shares in Q2 2026, an estimated $300M.
- Avoro Capital Advisors first reported a position in Terns Pharmaceuticals in Q4 2025 and held it in 2 quarters.
- Avoro Capital Advisors's Terns Pharmaceuticals position peaked at $300M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.
Based on Avoro Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.